Author:
Resch B.,Bramreiter V. S.,Kurath-Koller S.,Freidl T.,Urlesberger B.
Funder
Medical University of Graz
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference35 articles.
1. Resch B, Resch E, Müller W (2013) Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favor. Paediatr Respir Rev 14:130–136
2. Resch B, Gusenleitner W, Müller WD, Haas J (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25:120–122
3. Zaknun D, Resch B, Jürgenssen O, Sterniste W, Kaulfersch W, Schweintzger G et al (2001) Prevention of respiratory syncytial virus (RSV) infection in preterm infants with palivizumab (GERMAN). Monatsschr Kinderheilkd 149:176–178
4. American Academy of Pediatrics, Committee on Infectious Diseases (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102:1211–1216
5. Resch B, Urlesberger B, Müller W, Berger A (2004) Recommendations for respiratory syncytial virus prophylaxis with palivizumab (Synagis®) — update 2003 (GERMAN). Monatsschr Kinderheilkd 152:223–224
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献